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Background. Due to the predominantly advanced stage at the time of diagnosis treatment of cholangiocarcinoma is diﬃcult. Apart
from surgical resection, interventional treatment strategies are increasingly used in advanced stage tumours. The aim of the study
was a retrospective comparison of the eﬀect of the various forms of treatment on morbidity and mortality. Method.At o t a lo f
195 patients, received either chemotherapy or a combination of photodynamic therapy (PDT) or transarterial chemoembolization
(TACE) and chemotherapy. Results. The median survival rate for all patients was 15.6 months, 50.8% were still alive 1 year after
diagnosis. Patients, who had previously undergone surgery, survived 17.1 months longer than those without surgical treatment
(P<. 01). Chemotherapy prolonged the survival by 9.2 months (P = .47). Palliative patients under combination of chemotherapy
and PDT survived on average 1.8 months longer (P = .28), with chemotherapy and TACE 9.8 months longer (P = .04) compared
to chemotherapy alone. Conclusions. It appears that surgical treatment and chemotherapy combined with PDT or TACE may
prolong survival.
1.Introduction
Carcinomasofthebiletract,amalignantneoplasiaspreading
from the bile duct epithelia, were described for the ﬁrst time
as tumours of the common hepatic duct by Durand-Fardel
in 1840.
20–25% of all tumours are located intrahepatic, 50–60%
perihilar, and 20–25% extrahepatic [1, 2]. The classiﬁcation
by Bismuth et al. [3] groups perihilar tumours located in
the main branches of the biliary tree into four diﬀerent
categories. Type I tumours are limited to the common
bile duct and are located more than 2 cm away from the
conﬂuence of right and left hepatic ducts while type II
tumours involve the conﬂuence. Type III tumours involve
either the right (IIIa) or left (IIIb) hepatic duct while type
IV tumours extend to both ducts or are located multifocally.
“Klatskin” tumours are those with involvement of the
hepatic duct bifurcation [4]. Today, cholangiocarcinoma is
the second most frequent primary tumour disease of the
liver, nevertheless, the prevalence rate is relatively low (2-
3/100,000) compared with other tumours of the gastroin-
testinal tract [5, 6].
Due to the predominantly advanced tumour stage at
the time of diagnosis, therapy of cholangiocarcinoma and
gallbladder carcinoma remains diﬃcult [7]. Currently, the
only curative treatment is R0 resection [8]. However, in the
m a j o r i t yo fc a s e sa d v a n c e dt u m o u rs p r e a da n dl y m p hn o d e
involvement require a palliative approach. Surgical therapy2 Gastroenterology Research and Practice
of perihilar Klatskin tumours depends on the Bismuth
classiﬁcation. Tumour of types I and II are treated with en-
bloc resection of the extrahepatic bile ducts and the gall-
bladder, regional lymphadenectomy, and Roux-Y hepatico-
jejunostomy. In case of type III tumours an additional left
or right hemihepatectomy is performed, whereas type IV
tumours necessitate additional extended hemihepatectomy.
Thesurvivalrateofpatientswithintrahepatictumoursis18–
24 months depending on the hilar inﬁltration [9].
Unresectable bile duct and gallbladder tumours are
associated with a very poor prognosis. Apart from the
recommendation for best supportive care, adequate drainage
of the bile ducts with plastic or metal stent via endoscopic
retrograde cholangiography (ERC) is an important element
of the mainly palliative therapy [8, 10].
B i l ed u c tt u m o u r sa sw e l la sg a l l b l a d d e rt u m o u r sa r e
moderately chemotherapy-sensitive tumours. So far there is
nostandardprotocol,thuspatientsingoodgeneralcondition
or with tumour-associated symptoms should be included
in clinical trials evaluating palliative chemotherapy. For
example, prolonged survival (4 months) and higher quality
of life are reported for a small prospective randomised
trial evaluating the combination of 5-FU/Leucovorin and
Etoposide versus “best supportive care”; however these data
are without signiﬁcance [11]. Other study protocols cover
treatment with gemcitabine or 5-FU as monotherapy as well
as in combination with cisplatin and the combination of
capecitabine with cisplatin/5-FU. The available data world-
wide show that there might be a possibility to document
the beneﬁt of certain substances in trials with suﬃciently
large numbers of patients. Apart from the application of
chemotherapeutic drugs interventional procedures applied
and evaluated, for example transarterial chemoembolisation
(TACE) [12, 13].
Another procedure is photodynamic therapy (PDT),
whereby patients are given a photosensitizing agent (for
example photofrin), which increasingly accumulates in
malignant cells. Thereafter, transpapillary or percutaneous
radiation with light of a speciﬁc wave length activates the
sensitizing agent and generates reactive oxygen radicals. This
leads to destruction of the tumour cells. In the early 1990’s
McCaughan reported on the ﬁrst successful application
of photodynamic therapy in the treatment of bile duct
carcinoma [14]. A prospective study by Ortner et al. in the
late 1990’s showed a signiﬁcant positive eﬀect of PDT with
Photofrin in combination with biliary stenting compared to
drainage alone [15]. There are other studies conﬁrming this
tendency [16–21].
To date no comparative data are available on patients,
who received chemotherapy alone or a combination of PDT
or TACE and chemotherapy.
The aim of this retrospective study was to explore and
compare data of a selective patient group with bile duct
tumours treated with various forms of therapy regarding
their eﬀect on morbidity and mortality. All patients were
treatedintheGastroenterologicalDayClinicofMedizinische
Hochschule Hannover (MHH).
2.MaterialandMethods
2.1. Data Collection. All patients undergoing treatment for a
malignant bile duct tumour in the Gastroenterological Day
Clinic of MHH between 1999 and 2005 were included in a
retrospective analysis. The followup covered the period from
diagnosis to death or last contact with the day clinic. Patient
data were obtained from the MHH documentation system
ALIDAandtheH.I.T.databankoftheMHHTumourCentre
and entered into an individual own data bank (Microsoft
Excel 2003, Germany).
The following data were collected: gender, date of
birth, date of diagnosis and death, or date of last contact
with the patient, height, body weight, BMI, localisation of
the tumour, histology, histological/cytological conﬁrmation,
presence of various risk factors and symptoms, UICC/TNM
classiﬁcation, tumour markers CEA and CA 19-9, laboratory
parameter (bilirubin, Quick, albumin, cholinesterase, GGT,
ALT,andAST),previousoperations andR-classiﬁcation,and
reason of death.
The patients were divided into two subgroups according
to tumour localisation (ICD) and therapy distinguishing
betweenpatientswithmalignanttumoursoftheintrahepatic
(C22.1) and extrahepatic bile ducts (C24.0), particularly
Klatskin tumours of the hepatic duct bifurcation according
to Bismuth.
2.2.Therapy. Generally,thepatientsreceivedgemcitabinei.v.
as chemotherapeutic drug. Alternatively, a combination of
gemcitabine and cisplatin, gemcitabine, and oxaliplatin, 5-
FU or 5-FU and oxaliplatin was applied.
Photodynamic therapy was performed in 3 sessions at 6
week intervals via ERC or PTCD according to the procedure
established by Ortner/Berr et al. All patients received the
photosensitizing agent Photofrin.
TACE was performed in the Radiological Department
of MHH. After fasting a catheter was inserted into the
patients’ femoral artery and under radiological control an
embolizingagentwasinjectedintothebloodvesselsupplying
the tumour.
2.3. Statistics. The Kaplan-Meier survival curves were pro-
duced using PASW 18.0.2 (SPSS, Somers/NY, USA), and the
prognosis in the subgroups compared using log rank test.
Thepatientsweredividedintotwosubgroups(surgeryversus
palliation)anduni-andmultivariateanalysisofhazardratios
wasperformedusingCoxregression.AP-value< .05showed
signiﬁcancy. Because of the small numbers of patients in
each subgroup it was diﬃcult to show a valid diﬀerentiated
and stable multivariate analysis. The complete followup was
surveyed,andinviewoftheknownshortlifeexpectancyafter
diagnosis a 3-year survival rate was also determined and the
remaining patients were censored.
3. Results
As Table 1 shows a total of 195 patients were included in the
study,84females(43.1%)and111males(56.9%).AtthetimeGastroenterology Research and Practice 3
Table 1: Age, localisation, therapies, and results of all patients with diagnosis of cholangiocarcinoma.
Variables Total (n) Women (n) Men (n)
(n = 195) (n = 84) (n = 111)
Median age at point of diagnosis 58.47 (±12.28) 56.83 (±10.74) 59.70 (±13.24)
Median age at point of death 59.62 (±11.97) 58.12 (±11.03) 60.71 (±12.57)
Localisation
C22.1 111 (56.9%) 48 (57.1%) 63 (56.8%)
C24.0 84 (43.1%) 36 (42.9%) 48 (43.2%)
Therapy
OP 63 (34.1%) (n = 185) 28 (35.4%) (n = 79) 35 (33.0%) (n = 106)
adjuvant chemotherapy 15 (8.2%) (n = 183) 7 (9.0%) (n = 78) 8 (7.6%) (n = 105)
photodynamic therapy 14 (7.7%) (n = 183) 6 (7.6%) (n = 79) 8 (7.7%) (n = 104)
TACE 18 (9.8%) (n = 183) 12 (15.2%) (n = 79) 6 (5.8%) (n = 104)
chemotherapy 137 (80.6%) (n = 170) 60 (83.3%) (n = 72) 77 (78.6%) (n = 98)
Results of therapy (n = 184) (n = 81) (n = 103)
no tumor 11 (6.0%) 7 (8.6%) 4 (3.9%)
complete remission 6 (3.3%) 4 (4.9%) 2 (1.9%)
partial remission 4 (2.2%) 1 (1.2%) 3 (2.9%)
Reduction of tumor mass without def. Rem. 6 (3.3%) 1 (1.2%) 5 (4.9%)
unchanged 8 (4.3%) 2 (2.5%) 6 (5.8%)
progress 140 (76.1%) 62 (76.5%) 78 (75.7%)
no result of primary therapy 9 (4.9%) 4 (4.9%) 5 (4.9%)
Survival after (n = 195) (n = 84) (n = 111)
3 months 165 (84.6%) 74 (88.1%) 91 (82.0%)
6 months 140 (71.8%) 65 (77.4%) 75 (67.6%)
12 months 99 (50.8%) 47 (56.0%) 52 (46.8%)
Event of death 154 (80.6%) (n = 191) 65 (80.2%) (n = 81) 89 (80.9%) (n = 110)
of diagnosis the median age was 58.47 years (females: 56.82
years, males: 59.7 years.); at the time of death the median age
was 59.62 years (females 58.12 years, males 60.71 years).
111 patients (56.9%) suﬀered from a tumour of the
intrahepatic bile ducts (ICD C22.1) and 84 patients (43.1%)
had an extrahepatic tumour (ICD C 24.0), for example, at
the hepatic bifurcation (according to Bismuth).
Initially 3.7% (females 5.6%, males 2.2%) were at UICC
stage IA, 14.6% (females: 19.4%, males: 10.9%) at stage IB,
19.5% (females: 19.4%, males: 19.6%) at stage IIA, 20.7%
(females: 19.4%, males: 21.7%) at stage IIB, 11.0% (females:
13.9%, males: 8.7%) at stage III, and ﬁnally 30.5% (females:
22.2%, males: 37.0%) at stage IV.
The average survival after diagnosis was 15.6 months
(females:17.43months,males:14.43months).Threemonths
after commencement of treatment, 165 (84.6%) of the 195
patients had survived (88.1% of females, 82.0% of males).
After6monthsthesurvivingnumberofpatientswasreduced
to 140 (71.8% females of 77.4%; males 67.6%), and after 1
year only half of all patients (50.8% females of 56.0; males
46.8%) surveyed since commencement of treatment had
survived.
Around a quarter (26.5%) of the male patients and
a third (33.8%) of the female patients suﬀered from a
preexisting cholelithiasis. 11.8% of the males and 6.8% of
the females suﬀered from primary sclerosing cholangitis and
5.8% of the males and 4.1% of the females suﬀered from
ulcerative colitis. Liver cirrhosis was diagnosed in 15.5% of
the males and in 8.0% of the females. 1.0% of the males and
4.1% of the females suﬀered from primary biliary cirrhosis.
During the course of the treatment mild or moderate ascites
was diagnosed in 17.5% of the males and 14.2% of the
females. Thrombosis of the portal vein was seen in 6.2% of
male patients and 12.7% of female patients.
In the majority of patients serum concentrations of
bilirubin, cholinesterase, and coagulation parameters were
within normal; the albumin concentration was reduced in
one third (31.5%) of the females and a quarter (25.9%) of
the males. The mean value determined for CEA was 21µg/L
(standard deviation ±84µg/L) and CA 19-9 1521U/L (stan-
dard deviation 3588U/L) in males. For females the value
determined for CEA was 8µg/L (standard deviation 27µg/L)
and 13161U/L (standard deviation 84518U/L) for CA 19-9.
Transaminases and GGT were elevated in all patients.
63 (34.1%) patients had previously undergone surgery,
15(8.2%)patientsreceivedadditionalperioperativeadjuvant
chemotherapy.
137 (80.6%) patients (60 females, 77 males) received
chemotherapy in the Gastroenterological Day Clinic. 14
(7.7%) patients (6 females, 8 males) were treated with
photodynamic therapy (PDT), and 18 (9.8%) patients (12
females. 6 males) were treated with transarterial chemoem-
bolization. PDT was performed in 2 sessions (median, range
1–4 sessions).4 Gastroenterology Research and Practice
However, at the end of the observation period, the result
in the vast majority of patients (76.1%) was progression of
the tumour disease. In 6% of the patients (approximately
twice as many females as males) the tumour was no longer
visible. Complete remission could be assumed in 3.3% and
partial remission in 2.2% of the patients. In 3.3% a reduction
of the tumour mass without deﬁned remission could be
assumed. In 4.9% no eﬀect of the primary treatment was
observed.
At the end of the observation period 80.6% of patients
had died independent of gender.
93.5% (females 95.4%, males 92.2%) of all patients died
by progression of the tumour’s disease while only 1.9%
(females: 0%, males: 3.3%) died by cardiovascular diseases
(e.g., heart attack, stroke etc.). 4.5% (females 4.6%, males
4.4%) died by other diseases like sudden death of unknown
reason, infection, liver failure, and so forth.
If death was caused by tumour progression 42.9%
(females: 40.0%, males: 44.4%) of all patients being eval-
uated by UICC—classiﬁcation was at UICC stage IV ((IA
3.6% (females: 5.0%, males: 2.8%), IB 7,1% (females: 10.0%,
males: 5.6%), IIA 23.2% (females: 25.0%, males: 22.2%), IIB
16.1% (females: 10.0%, males: 19.4%), III 7.1% (females:
10.0%, males: 5.6%)). The Cox regression analysis showed
a higher hazard ratio for patients with UICC stage IIa and
more. The risk was signiﬁcantly higher after univariate anal-
ysis (P = .008) and insigniﬁcantly higher after multivariate
analysis (P = .18).
The median survival time of patients, who had under-
gone surgery was 27.1 months, that is, the survival time
was 17.1 months longer compared to those patients without
primarysurgicaltreatment(P<. 01).Coxregressionanalysis
additionally showed the hazard ratio was minimized signif-
icantly by this treatment (univariate P<. 0001/multivariate
P = .029). With adjuvant chemotherapy a median survival
time of 33.4 months (P<. 49) could be achieved, however,
this was statistically insigniﬁcant (Table 2). The hazard ratio
was signiﬁcantly lower in univariate but not in multivariate
analysis (P = .005/P = .18) (Figure 3).
A comparison of all patients (operated or palliative
care) who were treated with chemotherapy in the Gastroen-
terological Day Clinic and patients without chemotherapy
(Table 2) revealed that chemotherapy prolonged survival by
a median of 9.2 months, which was statistically insigniﬁcant
(P = .47). Univariate Cox regression showed a reduction
of hazard ratio but without signiﬁcancy (P = .47) while
multivariate analysis showed a higher risk for patients
undergoing chemotherapy which was also insigniﬁcant (P =
.25) (Figure 3). As in the majority of cases patients with
gastrointestinal tumours were treated with gemcitabine and
the number of patients treated with an alternative substance
was low, the Kaplan-Meier analysis distinguished only these
two subgroups. First-line chemotherapy with gemcitabine
revealed no advantage compared to other substances. In fact,
there were statistically signiﬁcant advantages for patients
treated with alternative substances (P<. 05).
Concerning the interventional therapy groups it was
noted that patients, who underwent photodynamic therapy
survived 19.3 months compared to 15.5 months without
Table 2: Median 3-year survival (IQR) under conservative versus
interventional therapies including all patients with cholangiocarci-
noma.
Therapy Total (n) Median survival
(months)
Signiﬁcance (P)
OP 61 27.1 (14.9)
No OP 121 10.0 (15.1) <.001
Adjuvant
chemotherapy
14 33.4 (27.1)
No adj. chemo 47 26.6 (14.9) .49
Chemotherapy 136 17.4 (20.4)
No
chemotherapy
33 8.2 (3) .466
PDT 14 19.3 (19.4)
No PDT 166 15.5 (27.3) .488
TACE 18 22.0 (16.7)
No TACE 162 14.5 (22.8) .190
photodynamic treatment. Again, there was no statistical
signiﬁcance(P = .49).Uni-andmultivariateanalysisshowed
a risk reduction which was not signiﬁcant (P = .49/P = .52).
In the group treated with transarterial chemoembolization
survival was insigniﬁcantly prolonged by 7.5 months (P =
.19) (Table 2) and the hazard ratio was also insigniﬁcantly
lowered (P = .19/P = .25) (Figure 3).
When looking at the various factors, which could
have an inﬂuence on the average 3-year survival rate,
marked formation of ascites (P<. 001), previously present
cholelithiasis (<.05), metastases (P<. 001), reduced albumin
concentration (P<. 05), and reduced concentration of
cholinesterase (<.05), elevated GGT (P<. 01) and CEA
(P<. 05)wereidentiﬁed.TheCoxregressionanalysisshowed
the hazard ratio was insigniﬁcantly higher for patients at an
age of >60 years (P = .062/P = .62) but insigniﬁcantly lower
for women (P = .2/P = .5)
As several studies dealing with the treatment of CCC
patients with photodynamic therapy and stenting, but there
are few data available on a combination of chemotherapy
and photodynamic therapy or TACE, these patients were
analysed separately in a “palliation only group” (n = 95).
Patients under chemotherapy had a lower risk both in
univariate and multivariate Cox regression (P<. 001/P<
.05) (Table 3). Median survival was 11.7 months longer than
without chemotherapy (P<. 05). Patients treated with a
combination of chemo- and photodynamic therapy survived
1.8 months longer than those treated with chemotherapy
alone (Table 3). However, there was no statistical signiﬁcant
diﬀerence (P = .28) (Figure 1) both in Kaplan-Meier-
analysis and Cox regression (univariate/multivariate P =
.23). The result for patients treated with a combination of
TACE and chemotherapy was similar (Figure 2). Additional
transarterialchemoembolizationprolongedthesurvivaltime
by 9.8 months, which has statistical signiﬁcance (P<
.05) in Kaplan-Meier-analysis (Table 3) and univariate Cox
regression (P<. 05) but not in multivariate analysis (P =
.06).Gastroenterology Research and Practice 5
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Figure 1: 3-years-Kaplan-Meier estimate for chemo versus photo-
dynamic therapy (P = .28) in patients with cholangiocarcinoma
(palliation group).
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Figure 2: 3-years-Kaplan-Meier estimate for chemo versus transar-
terial chemoembolisation (P = .04) in patients with cholangiocar-
cinoma (palliation group).
4. Discussion
To date no standard therapy has been established for patients
with malignant tumours of the bile ducts. As this is a disease
with a low but increasing incidence rate, the majority of
patients are treated in clinical trials with protocols which
vary considerably. In the majority of cases the disease is not
diagnosed in the advanced stage. This complicates planning
the therapy, which subsequently is palliative in most cases.
Table 3: Median 3-year-survival (IQR) of patients with cholan-
giocarcinoma undergoing stand-alone chemotherapy versus com-
bination of chemotherapy and interventional therapies (palliation
group).
Therapy Total (n) Median survival
(months)
signiﬁcance (P)
Chemo + PDT 11 16.3 (10.9)
Chemo 84 14.5 (16.9) .283
Chemo + TACE 14 22.0 (10)
Chemo 81 12.2(16.6) .039
Our results partially correspond with those reported in
numerouspublications.Theshortsurvivaltimeof1yearand
3monthsfromdiagnosistodeathcorrelateswiththesurvival
times reported in known studies [22–24]. The high mortality
rate with 50% within 1 year after diagnosis emphasises the
great malignity of these tumours, and the currently mostly
futile therapeutic eﬀorts to achieve long-term remission or
cure.
The association of signiﬁcantly elevated or reduced val-
uesforcholinesterase,albuminGGT,andCEAwithashorter
survivaltimecanbeexplainedbytheseverelyimpairedorgan
function in the advanced stage of the disease. Marked ascites
and metastases are to be seen in the same context as uni-
and multivariate analysis of the UICC stages additionally
show. The survival was signiﬁcantly reduced in patients, who
suﬀered from cholelithiasis prior to the diagnosis of CCC.
The predominant opinion is that chronic inﬂammatory
stimulation of the cells caused by the permanent eﬀectof bile
acid is to be considered potentially malignant and inﬂuence
the development of CCC [23, 25, 26].
Surgical treatment signiﬁcantly improved the survival
rate of patients treated at MHH. Kahn et al. [23], Yamamoto
et al. [27], and Chen et al. [28] could already show
similar results in three studies on surgical resection of CCC.
Therefore, surgical resection remains to present the only
sensible therapeutic measure with a curative approach at
present.Adjuvantchemotherapyprolongedthesurvivaltime
by approximately 6 months, which is contrary to various
reports [22]. Takada et al. [29] could not see any advantages
of adjuvant chemotherapy in his frequently cited work. The
most likely reason for our diﬀering result could be the
small case number (n = 63), particularly as the data were
statistically signiﬁcant (P<. 05) only in univariate Cox
regression analysis but insigniﬁcant in Kaplan-Meier (P =
.49) and multivariate analysis (P = .18).
There were only a small number of patients in our
observation group suﬀering from liver cirrhosis additionally
(15.5% of males, 8.0% of females). Since all patients
could be classiﬁed as Child-Pugh-Score A, and today liver
transplantation seems to be an option for patients with
cholangiocarcinoma only in experimental settings [30]w e
treated them like all diﬀerent.
On average the survival time of patients, who in view
of the hopeless prognosis underwent primary chemotherapy
with gemcitabine or alternative substances in a palliative
approach, was prolonged by approximately 12 months.6 Gastroenterology Research and Practice
Uni- and multivariate hazard ratios of Cox regression
(with 95%-CI)
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Figure 3: Uni- and multivariate analysis of hazard ratios by Cox regression method for all patients with cholangiocarcinoma.
Uni- and multivariate hazard ratios of Cox regression
of palliation group (with 95%-CI)
Univariate Multivariate
Age ≥ 60
Female
TACE
Chemotherapy
Hazard ratio Hazard ratio
P = .15
P = .521
P = .024
P = .001
P = .232
P = .748
P = .408
P = .058
P = .007
P = .23
0 0.5 1 1.5 2 2.5 0 0.5 1 1.5 2 2.5
Photodynamic therapy
Figure 4:Uni-andmultivariateanalysisofhazardratiosbyCoxregressionmethodforpatientswithcholangiocarcinoma(palliationgroup).Gastroenterology Research and Practice 7
Table 4: Series published on PDT.
Author Year Patients (n) Median survival (months)
Ortner et al. 1998 9 14.4 (3.0–18.9)
Berr et al. 2000 23 11.1 (0.8–50.7)
Rumalla et al. 2001 6 >9
Dumoulin et al. 2003 24 9.9 (2–39)
Ortner et al. 2003 20 16.3 (9.1–23.3)
Zoepf et al. 2005 16 21
Shim et al. 2005 24 18.6 (2–27)
Total 188 9.9–21
However, these observations correspond with studies that
could show an improved survival with similar therapeutic
regimens [31]. As the number of patients was small, we
decided to divide the patient collective into two groups, one
gemcitabine group and one group treated with alternative
substances, for example, 5-FU, oxaliplatin or cisplatin. This
revealed a signiﬁcant advantage for the alternative group
(P = .05). The available studies on the application of
various chemotherapeutics appear to be very heterogenic. A
whole range of substances are used, but the case numbers
are generally small. The majority of studies are aﬀected by
the lack of randomisation. Eckel and Schmidt performed
a meta-analysis of all studies on chemotherapy for CCC.
This showed that a combination of gemcitabine and cisplatin
or oxaliplatin achieved the best response rate and the
most eﬀective control of tumour growth [10]. In this
context the survival advantage observed in our patients,
whoweretreatedwithchemotherapyotherthangemcitabine
monotherapy, appears conclusive.
In recent years interventional therapies such as photo-
dynamic therapy or TACE were used successfully in a small
selective patient group, mostly in combination with stenting
of obstructed bile ducts [10, 32–35]( Table 4). Due to the
signiﬁcantly prolonged survival of the patients the frequently
cited study by Ortner was prematurely terminated. The study
by Dumoulin at least conﬁrmed that photodynamic therapy
combined with stenting considerably improved quality of
life.
The patients we treated with PDT or TACE also bene-
ﬁtted from this interventional strategy. Combination of sys-
temic chemotherapy and interventional therapy prolonged
the survival time by a few months. Even if there was no
statistical signiﬁcance this result indicates an advantage of
combined conservative and interventional therapy. However,
this should be veriﬁed in larger studies as the validity is
limited by the small number of patients and the retrospective
design of this study.
Finally, many factors like missing randomisation can bias
the results of a retrospective study, that is, the eﬀect of
an applied therapy. Observation bias may occur because of
misclassiﬁcation or recall mistakes and frequently a number
of patients are lost to followup. Criteria to select patients
for diﬀerent kinds of treatments vary during the years and
in diﬀerent hospitals. Due to the nature of rare diseases the
possibility of observation is limited.
5. Conclusion
Due to the late diagnosis, low incidence rate and great
malignity tumours of the bile duct are a great challenge to
physician. Due to the frequent lack of randomisation many
studies have only limited validity and thus complicate the
search for a gold standard in the treatment of these tumours.
The results shown in this retrospective study merge with
the number of new studies indicating a favourable inﬂuence
on survival of combined conservative and interventional
procedures. However, it is diﬃcult to obtain reliable data
due to a small number of cases, a heterogenic patient group,
and partially inadequate documentation. Future studies with
larger patient groups for the therapeutic options presented
are desirable, to achieve advances in the therapy of these
highly malignant tumours.
References
[1] M. J. Olnes and R. Erlich, “A review and update on cholangio-
carcinoma,” Oncology, vol. 66, pp. 167–179, 2004.
[2] S. Kubicka, “Cholangiozellul¨ ares Karzinom und Gallen-
blasenkarzinom,” Zeitschrift f¨ ur Gastroenterologie, vol. 42, no.
5, pp. 397–402, 2004 (German).
[3] H. Bismuth and P. E. Majno, “Hepatobiliary surgery,” Journal
of Hepatology, vol. 32, supplement 1, pp. 208–224, 2000.
[4] G. Klatskin, “Adenocarcinoma of the hepatic duct at its
bifurcation within the porta hepatis. An unusual tumor with
distinctive clinical and pathological features,” The American
Journal of Medicine, vol. 38, no. 2, pp. 241–256, 1965.
[5] S. A. Khan, H. C. Thomas, B. R. Davidson, and S. D. Taylor-
Robinson, “Cholangiocarcinoma,” Lancet, vol. 366, no. 9493,
pp. 1303–1314, 2005.
[6] S. Misra, A. Chaturvedi, N. C. Misra, and I. D. Sharma,
“Carcinoma of the gallbladder,” Lancet Oncology, vol. 4, no.
3, pp. 167–176, 2003.
[7] J. Schmielau, J. Klempnauer, and W. Schmiegel, “Cholan-
giokarzinome,” Internist, vol. 38, no. 10, pp. 970–976, 1997
(German).
[ 8 ]D .M a l k a ,V .B o i g e ,C .D r o m a i n ,T .D e b a e r e ,M .P o c a r d ,a n d
M. Ducreux, “Biliary tract neoplasms: update 2003,” Current
Opinion in Oncology, vol. 16, no. 4, pp. 364–371, 2004.
[ 9 ]S .J o n a s ,T .R ¨ osch, and P. Neuhaus, “Treatment options
for cholangiocarcinomaTherapieoptionen beim Hepatikusga-
belkarzinom,” Gastroenterologe, vol. 3, no. 1, pp. 22–32, 2008
(German).
[10] F. Eckel and R. M. Schmid, “Chemotherapy in advanced
biliary tract carcinoma: a pooled analysis of clinical trials,”
British Journal of Cancer, vol. 96, no. 6, pp. 896–902, 2007.
[11] B. Glimelius, K. Hoﬀman, P. O. Sj¨ od´ en et al., “Chemotherapy
improves survival and quality of life in advanced pancreatic
and biliary cancer,” Annals of Oncology, vol. 7, no. 6, pp. 593–
600, 1996.
[12] I. Burger, K. Hong, R. Schulick et al., “Transcatheter arterial
chemoembolization in unresectable cholangiocarcinoma: ini-
tial experience in a single institution,” Journal of Vascular and
Interventional Radiology, vol. 16, no. 3, pp. 353–361, 2005.
[13] T. Kirchhoﬀ, L. Zender, S. Merkesdal et al., “Initial experience
fromacombinationofsystemicandregionalchemotherapyin
the treatment of patients with nonresectable cholangiocellular
carcinoma in the liver,” World Journal of Gastroenterology, vol.
11, no. 8, pp. 1091–1095, 2005.8 Gastroenterology Research and Practice
[14] J. S. McCaughan, B. F. Mertens, C. Cho, R. D. Barabash, and
H. W. Payton, “Photodynamic therapy to treat tumors of the
extrahepatic biliary ducts. A case report,” Archives of Surgery,
vol. 126, no. 1, pp. 111–113, 1991.
[15] M. A. E. J. Ortner, J. Liebetruth, S. Schreiber et al., “Pho-
todynamic therapy of nonresectable cholangiocarcinoma,”
Gastroenterology, vol. 114, no. 3, pp. 536–606, 1998.
[16] F. Berr, M. Wiedmann, A. Tannapfel et al., “Photodynamic
therapy for advanced bile duct cancer: evidence for improved
palliationandextendedsurvival,”Hepatology,vol.31,pp.291–
298, 2000.
[17] M. E. J. Ortner, K. Caca, F. Berr et al., “Successful pho-
todynamic therapy for nonresectable cholangiocarcinoma: a
randomized prospective study,” Gastroenterology, vol. 125, no.
5, pp. 1355–1363, 2003.
[18] G. C. Harewood, T. H. Baron, A. Rumalla et al., “Pilot study
to assess patient outcomes following endoscopic application
of photodynamic therapy for advanced cholangiocarcinoma,”
Journal of Gastroenterology and Hepatology,v o l .2 0 ,n o .3 ,p p .
415–420, 2005.
[19] F. L. Dumoulin, T. Gerhardt, S. Fuchs et al., “Phase II study of
photodynamic therapy and metal stent as palliative treatment
for nonresectable hilar cholangiocarcinoma,” Gastrointestinal
Endoscopy, vol. 57, pp. 860–867, 2003.
[20] C. S. Shim, Y. K. Cheon, S. W. Cha et al., “Prospective study of
the eﬀectiveness of percutaneous transhepatic photodynamic
therapyforadvancedbileductcancerandtheroleofintraduc-
tal ultrasonography in response assessment,” Endoscopy, vol.
37, no. 5, pp. 425–433, 2005.
[21] T. Zoepf, R. Jakobs, J. C. Arnold et al., “Palliation of
nonresectable bile duct cancer: improved survival after pho-
todynamictherapy,”TheAmericanJournalofGastroenterology,
vol. 100, pp. 2426–2430, 2005.
[ 2 2 ]S .A .K h a n ,S .D .T a y l o r - R o b i n s o n ,M .B .T o l e d a n o ,A .B e c k ,
P. Elliott, and H. C. Thomas, “Changing international trends
in mortality rates for liver, biliary and pancreatic tumours,”
Journal of Hepatology, vol. 37, no. 6, pp. 806–813, 2002.
[23] S.A.Khan,B.R.Davidson,R.Goldinetal.,“Guidelinesforthe
diagnosis and treatment of cholangiocarcinoma: consensus
document,” Gut, vol. 51, supplement 6, pp. VI1–VI9, 2002.
[24] G. J. Gores, “A spotlight on cholangiocarcinoma,” Gastroen-
terology, vol. 125, no. 5, pp. 1536–1538, 2003.
[25] D. Malka, V. Boige, C. Dromain, T. Debaere, M. Pocard, and
M. Ducreux, “Biliary tract neoplasms: update 2003,” Current
Opinion in Oncology, vol. 16, no. 4, pp. 364–371, 2004.
[26] T. Ben-Menachem, “Risk factors for cholangiocarcinoma,”
European Journal of Gastroenterology and Hepatology, vol. 19,
no. 8, pp. 615–617, 2007.
[27] J. Yamamoto, T. Vosuge, T. Takayama et al., “Surgical
treatment of intrahepatic cholangiocarcinoma: four patients
surviving more than 5 years,” Surgery, vol. 111, p. 617, 1992.
[ 2 8 ] M .F .C h e n ,Y .Y .J a n ,C .S .W a n g ,L .B .J e n g ,a n dT .L .H w a n g ,
“Clinical experience in 20 hepatic resections for peripheral
cholangiocarcinoma,” Cancer, vol. 64, no. 11, pp. 2226–2232,
1989.
[29] T. Takada, H. Amano, H. Yasuda et al., “Is postoperative
adjuvant chemotherapy useful for gallbladder carcinoma?
A phase III multicenter prospective randomized controlled
trial in patients with resected pancreaticobiliary carcinoma,”
Cancer, vol. 95, no. 8, pp. 1685–1695, 2002.
[30] D. Alvaro, R. Canizzaro, R. Labianca et al., “Cholangio-
carcinoma: a position paper by the Italian Society of Gas-
troenterology (SIGE), the Italian Association of Hospital
Gastroenterology (AIGO), the Italian Association of Medical
Oncology (AIOM) and the Italian Association of Oncological
Radiotherapy (AIRO),” DigestiveandLiverDisease, vol. 42, no.
12, pp. 831–838, 2010.
[31] B.Glimelius,K.Hoﬀman,W.Grafetal.,“Cost-eﬀectivenessof
palliative chemotherapy in advanced gastrointestinal cancer,”
Annals of Oncology, vol. 6, no. 3, pp. 267–274, 1995.
[32] M. Ortner, “Photodynamic therapy for cholangiocarcinoma,”
Journal of Hepato-Biliary-Pancreatic Surgery,v o l .8 ,n o .2 ,p p .
137–139, 2001.
[33] A. Rumalla, T. H. Baron, K. K. Wang, G. J. Gores, L. M.
Stadheim, and P. C. De Groen, “Endoscopic application of
photodynamic therapy for cholangiocarcinoma,” Gastroin-
testinal Endoscopy, vol. 53, no. 4, pp. 500–504, 2001.
[34] F. L. Dumoulin, T. Gerhardt, S. Fuchs et al., “Phase II study of
photodynamic therapy and metal stent as palliative treatment
for nonresectable hilar cholangiocarcinoma,” Gastrointestinal
Endoscopy, vol. 57, no. 7, pp. 860–867, 2003.
[35] M. Wiedmann, F. Berr, I. Schiefke et al., “Photodymic therapy
in patients with non-resectable hilar cholangiocarcinoma: 5—
yearfollow-upofaprospectivephaseIIstudy,”Gastrointestinal
Endoscopy, vol. 60, p. 68, 2004.